12:30–13:30

Anabios

Room 119

Higher Throughput Human Cardiomyocyte Assay for Safety Screening

Dr. Najah Abi-Gerges will present data from AnaBios’ unique human primary cardiomyocyte assay. AnaBios recovers high-quality cardiomyocytes for assessing drug-induced cardiotoxicity. By leveraging new technologies for higher-throughput screening, AnaBios can now support medicinal chemistry early discovery efforts with rapid turnaround and data that are highly predictive of human safety risk.

07:00–08:00

Axion BioSystems

Room 119

Maturation of iPSC-CM Function for Improved Predictivity of In Vitro CM-MEA Assays

iPSC-CMs have significantly advanced in vitro assays for cardiac safety, but remain an immature representation of the human heart. In this seminar, attendees will learn how to mature cardiomyocytes for use in functional assays of the action potential, conduction, and contractility.

12:30–13:30

Emka Technologies

Room 121

Leveraging Machine Learning for Automated ECG and Hemodynamic Analyses

Cardiovascular safety scientists are using analysis software designed to streamline the evaluation of ECG and hemodynamic endpoints. While they increase efficiency, the need to evaluate larger datasets, with increased depth brings a significant level of human intervention and processing time, with inter-user variability. This study leverages historical data to guide a novel pattern recognition algorithm in performing automated cardiovascular analyses.

12:30–13:30

Nanion Technologies

Room 119

Future Technologies in Safety Pharmacology and Drug Discovery

Session focuses on HTS approaches for studying cardiac ion channels and iPSC-CMs in research, screening, and risk assessment. We will introduce recent iPSC-CMs maturation strategies such as recordings on flexible membranes, electrical stimulation and IK1 simulation during automated patch clamp recordings. CiPA conform best practices and progress for drug development will also be presented.

12:30–13:30

TARA Biosystems

Room 120

Using hiPSC-derived Tissues for Cardiac Risk Assessment: Translational Considerations

Translational fidelity is a key consideration when selecting the appropriate model for cardiac risk assessment. Such fidelity requires a platform that reproducibly recapitulates key structural and functional features of adult human cardiac tissue. We will discuss data demonstrating the translational relevance of TARA's in vitro iPSC-derived Cardiotype tissues.

18:00–19:00

ACEA Biosciences, Inc. - A part of Agilent

Room 119

Are Functionally Mature hiPSC-Cardiomyocytes More Predictive for Safety Assessment?

As the field determines how to improve the predictivity of cardiomyocyte models, the questions being raised are: What constitutes CM maturation and is it more a predictive model? To address these questions, we explored the role of electrical pacing using ACEA's high-throughput ePacer platform and retested a subset of Phase II CiPA compounds. We will discuss our results in this presentation.

18:00–19:00

ERBC

Room 120

Arrhythmic Risk Assessment: New Biomarkers for an Improved Translation from Preclinical QT Studies to Human

We recently published several translational studies demonstrating that increases in beat to beat variability of ventricular repolarization induced by torsadogenic drugs was related to a co-activation of both sympathetic and parasympathetic nervous systems. We derived several new biomarkers with promising sensitivity and specificity reflecting a risk of autonomic conflict, this latter concept being known to trigger torsades de pointes in LQT syndromes.

12:30–13:30

Data Sciences International

Room 120

Take a Deep Breath and Relax with Impedance on Your Side

Cardiopulmonary monitoring across non-rodent species is part of the modern safety pharmacology toolbox when assessing organ system interactions. Specificity and differences will be overviewed with data from canines, NHPs and minipigs. Digital data acquisition and animal welfare will also be explored. The session is built with ample time for an open discussion on applications and experience.

12:30–13:30

NanoSurface Biomedical

Room 119

Leveraging Structurally Matured iPSC-derived Cardiomyocytes for Predictive High-throughput Screening

iPSC-CMs hold great potential for assessing various cardiotoxicity mechanisms in vitro; however their full potential is limited by their expression of fetal and embryonic phenotypes. Learn how structural maturation can improve the predictive power of these cells in a variety of cell-based assays, and how this approach can be easily integrated into most industry-standard high-throughput assays.

12:30–13:30

NMI TT Pharmaservices

Room 121

hiPSC for Drug Development and Safety Assessment Using Live Kinetic and Electrophysiological Readout

Attend to learn how drug discovery challenges are being reduced by using iPSC-derived cardiomyocytes and 3D-neural spheroids with real-time, high-throughput functional methodologies to identify potential drug-induced effects and improve predictivity. The solutions will be presented by Udo Kraushaar from NMI and guest speakers Blake Anson from StemoniX and Stephane Bedut from E-physervices.